KOD · Nasdaq · USD · Market cap $2.5B · 130 employees
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
FAIL · Does not pass the screen
39.33 USD
At the last full screen 2026-08-26
Screened 2026-08-26 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Kodiak Sciences Inc. holds its Markdown at $39.33. The statistical read favours the sellers, held for 23 days.
As held on the ledger · 2026-08-26
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 23 days
Price at the screen
$39.33
Valuation
N/A trailing · -11.09 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.21
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
16.83%
Below 33%
Interest-bearing debt is just 16.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
59.70%
Below 49%
Money owed to the company is 59.7% of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. A 67.8% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus Strong Buy. The average target sits +68% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech eye drug bet lacks financial proof
Imagine a lab racing to treat failing eyesight with one unproven injection while the books show zero profit and deep losses. Kodiak Sciences sits in exactly that spot, a clinical stage developer of retinal therapies whose lead candidate still needs years of trials. We pass because the ethical screen returns insufficient data and the opportunity rating sits at none.
The numbers tell a clear story of early stage risk. Forward earnings sit at a negative 13.7 times, profit margins remain at zero and return on equity runs at minus 209 percent. Analyst targets hover around 60 dollars yet carry no consensus rating, leaving investors to guess at timing and success.
Currency and trial failure sit at the centre of the downside. A single missed endpoint or delayed approval could wipe out the apparent margin of safety without any operating cash flow to cushion the fall. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KOD trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-03Markdown · changed$39.33-7.8%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63.
2026-08-04Markup · changed$42.64+25.2%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 25.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63.
2026-07-18Markdown$34.06+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63.
2026-07-03Markdown$34.06+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$34.06Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
